KOL Mapping for Early-Phase and Pre-Launch Pharma Programmes
Early-PhasePre-LaunchClinical DevelopmentScientific Platform
The expert relationships that determine a therapy’s long-term commercial success are not built at launch. They are built in the years before launch — during early clinical development, when the science is still being defined, when the investigators who will run the pivotal trials are being identified, and when the scientific leaders who will shape how the therapy is understood at approval are first encountering the data. KOL Mapping by VML helps early-phase teams identify and begin building those relationships at the optimal point.
🔸 Why Early-Phase Teams Need Specialist KOL Mapping
- The disease area expert landscape is often poorly understood at early-phase stage — particularly for novel mechanisms, rare diseases, or indications entering new treatment paradigms
- Investigator selection for early trials is made from internal networks rather than systematic expert landscape intelligence — missing the most strategically important candidates
- Scientific advisory boards at early-phase are often constituted from familiar names rather than the experts best positioned to guide the programme’s scientific development
- The emerging experts who will be most influential at launch are invisible this early — creating a gap that later KOL mapping programmes cannot fully close
- Competitors investing in early-phase KOL mapping have a relationship-building head start of 3–5 years by the time a programme reaches launch
✓ How KOL Mapping by VML Supports Early-Phase Programmes
- Disease area expert landscape mapping — who defines the scientific frontier, who is driving the most important methodological advances, and who holds the emerging consensus positions your programme needs to understand
- Investigator landscape mapping — identifying the most credible and strategically appropriate PI candidates for early and pivotal trials
- Scientific advisory board design intelligence — the right mix of established authority, emerging perspective, and network diversity for the programme stage
- Emerging expert identification — rising stars who will be the most influential clinical voices at launch, available for relationship-building now at the lowest cost and highest authenticity
- Catalyst of change mapping — who is driving the shifts in disease understanding, diagnostic criteria, or therapeutic mechanism interpretation that will shape your programme’s regulatory and commercial environment
The Early-Phase KOL Mapping Opportunity
📈 Why Starting Early Compounds Advantage Over Time
✓ The early-mover advantage
A biotech company commissions KOL mapping at Phase I for a novel mechanism in a rare inflammatory condition. The mapping identifies twelve emerging clinical researchers — three years into their independent careers, with strong early publication trajectories and growing congress presence. The company’s medical affairs team begins building science-led relationships with all twelve, sharing early data, inviting several onto the scientific advisory board, and identifying two as potential PI candidates for the Phase II programme.
By Phase III, four of the twelve emerging experts have become established KOLs. Two are now principal investigators in the pivotal trial. All twelve have deep, authentic, relationship-based familiarity with the therapy’s science. At launch, the company has a network of twelve clinical advocates — each at the peak of their influence trajectory — whose understanding of the therapy is not manufactured by a pre-launch KOL programme, but built over five years of genuine scientific engagement.
✗ The late-mover reality
A competitor entering the same indication at Phase III discovers those same twelve experts on a standard pre-launch KOL list. They are now established KOLs with full advisory schedules, premium speaking fees, and existing competitor relationships. The competitor’s launch engagement programme is more expensive, less authentic, and starts from a significantly weaker relationship foundation than the early-mover’s programme built three years earlier.
Key Applications of Early-Phase KOL Mapping
| Application | What Mapping Provides |
|---|---|
| Disease area understanding | A complete picture of the current scientific frontier — who defines it, what the open questions are, and which emerging voices are contributing the most important advances |
| Investigator identification | Systematic identification of the most credible and network-connected PI candidates for early and pivotal trials — not just the sites your team already knows |
| Scientific advisory board design | The intelligence needed to constitute a scientific advisory board that reflects the full expert landscape — and will produce credible, strategically useful outputs |
| Publication strategy | Identifying the most appropriate and credible author networks for early-phase publication — building the scientific platform that will support regulatory and commercial strategy |
| Emerging expert pipeline | A watched list of rising stars to engage now — building the launch KOL network years before competitors have even started their pre-launch mapping exercise |
Frequently Asked Questions
Is early-phase KOL mapping relevant for rare disease programmes?
Particularly so. Rare disease expert communities are small, well-connected, and highly influential relative to their size. Investigator and scientific advisory board design choices in rare disease programmes have outsized impact on regulatory strategy, clinical guidelines, and patient community trust. Early identification and engagement of the right experts — including patient advocacy leaders as KEEs — is disproportionately valuable in rare disease compared to larger indication programmes. → Discuss rare disease expert mapping
Can early-phase KOL mapping be updated as a programme progresses through development stages?
Yes — and this is strongly recommended. The expert landscape evolves as a programme progresses. New researchers publish relevant findings, emerging experts reach new influence milestones, and the clinical community’s understanding of the disease area shifts. KOL Mapping by VML recommends refreshing expert landscape intelligence at each major programme milestone — Phase II initiation, Phase III initiation, and 18–24 months pre-submission — to ensure engagement priorities remain current. → Read: KOL Mapping for Launch Strategy
How does early-phase KOL mapping integrate with later pre-launch and launch mapping?
Early-phase mapping produces the foundation on which all subsequent KOL intelligence is built. Pre-launch mapping refreshes and extends this foundation — updating expert profiles, expanding geographic coverage, adding DOL mapping, and revalidating shortlists for launch activation. Organisations that invest in early-phase mapping require significantly less resource in their pre-launch mapping phase, because the expert landscape is already well-understood and relationships are already established. → Read: KOL Mapping for Launch Strategy
Start Building Your Expert Relationships at the Optimal Point in the Development Cycle
→ Book an early-phase KOL mapping conversation with KOL Mapping by VML